AccuMetab™ Human UGT2B7 Enzyme, Catalytically Active

CAT#: ITS-0426-YL99
Product Type: Recombinant Phase II Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human UGT2B7 for precise Phase II glucuronidation ADME screening.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
UGT2B7 is a highly critical Phase II enzyme that metabolizes a vast array of clinical drugs, including opioids, NSAIDs, and antiretrovirals. Because of its dominant role in the clearance of major therapeutics, assessing UGT2B7-mediated metabolism is a foundational requirement in all ADME programs.
Key Features
High-activity Sf9 insect cell microsome format; Dominant clearance pathway for opioids and AZT; Mandatory component of comprehensive ADME panels; Requires UDPGA cofactor for assay initiation
Applications
Phase II Drug Metabolism, Glucuronidation Studies
Research Areas
ADME; Phase II Conjugation
Species
Human
Expression System
Recombinant enzymes are prepared from baculovirus-infected Sf9 insect cells.
Physical Form
Liquid
Size
2.5 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry